Skip to main content
Top
Published in: BMC Gastroenterology 1/2020

Open Access 01-12-2020 | Ulcerative Colitis | Research article

Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis

Authors: Natsuki Ishida, Takahiro Miyazu, Ryosuke Takano, Satoshi Tamura, Shinya Tani, Takuma Kagami, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Takahisa Furuta, Hiroaki Miyajima, Ken Sugimoto

Published in: BMC Gastroenterology | Issue 1/2020

Login to get access

Abstract

Background

Prostaglandin E-major urinary metabolite (PGE-MUM) may be a novel biomarker for evaluating disease activity in ulcerative colitis (UC). We compared its usefulness to that of the fecal immunochemical occult blood test (FIT).

Methods

PGE-MUM and FIT measurements were performed of 92 urinary and fecal samples obtained from 60 patients with UC. Endoscopic activity was determined by Mayo endoscopic subscore (eMayo) and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score.

Results

PGE-MUM levels and FIT results showed a significant correlation with respect to eMayo (P <  0.001 and P < 0.001, respectively), and there was a significant difference in PGE-MUM values between the groups below eMayo1 and above eMayo2 (P = 0.012). Both biomarkers were significantly correlated with the UCEIS score (P < 0.001 and P < 0.001, respectively), and the PGE-MUM values were significantly different between groups below UCEIS1 and above UCEIS2 (P = 0.012). PGE-MUM and FIT were significantly correlated with eMayo in the group with a disease duration < 5 years (P = 0.041 and P < 0.001, respectively). Although PGE-MUM and eMayo differed significantly between groups over 5 years (P = 0.012), FIT was not correlated with eMayo (P = 0.101).

Conclusions

PGE-MUM is useful as a biomarker as FIT for evaluating the endoscopic activity, particularly in long-term affected patients with UC.
Literature
1.
2.
go back to reference Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107:3–11.CrossRef Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107:3–11.CrossRef
3.
go back to reference Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194–201.CrossRef Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194–201.CrossRef
4.
go back to reference Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661–5.CrossRef Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661–5.CrossRef
5.
go back to reference Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology. 2015;149:1275–85.CrossRef Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology. 2015;149:1275–85.CrossRef
6.
go back to reference Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009;15:1851–8.CrossRef Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009;15:1851–8.CrossRef
7.
go back to reference D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218–24.CrossRef D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218–24.CrossRef
8.
go back to reference Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Endoscopic score vs fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing. Clin Transl Gastroenterol. 2018;9:e136.CrossRef Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Endoscopic score vs fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing. Clin Transl Gastroenterol. 2018;9:e136.CrossRef
9.
go back to reference Arai Y, Arihiro S, Matsuura T, Kato T, Matsuoka M, Saruta M, et al. Prostaglandin E-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis. Inflamm Bowel Dis. 2014;20:1208–16.CrossRef Arai Y, Arihiro S, Matsuura T, Kato T, Matsuoka M, Saruta M, et al. Prostaglandin E-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis. Inflamm Bowel Dis. 2014;20:1208–16.CrossRef
10.
go back to reference Okayasu I, Ohnishi H, Sarandi I, Shojima J, Komatsu J, Oritsu M. Significant increase of prostaglandin E major urinary metabolite in male smokers a screening study of age and gender differences using a simple radioimmunoassay. J Clin Lab Anal. 2014;28:32–41.CrossRef Okayasu I, Ohnishi H, Sarandi I, Shojima J, Komatsu J, Oritsu M. Significant increase of prostaglandin E major urinary metabolite in male smokers a screening study of age and gender differences using a simple radioimmunoassay. J Clin Lab Anal. 2014;28:32–41.CrossRef
11.
go back to reference Horikiri T, Hara H, Saito N, Araya J, Takasaka N, Utsumi H. Increased levels of prostaglandin E major urinary metabolite (PGE MUM) in chronic fibrosing interstitial pneumonia. Respir Med. 2017;122:43–50.CrossRef Horikiri T, Hara H, Saito N, Araya J, Takasaka N, Utsumi H. Increased levels of prostaglandin E major urinary metabolite (PGE MUM) in chronic fibrosing interstitial pneumonia. Respir Med. 2017;122:43–50.CrossRef
12.
go back to reference Lichtiger S, Present DH. Preliminary report: Cyclosporin in treatment of severe active ulcerative colitis. Lancet. 1990;336:16–9.CrossRef Lichtiger S, Present DH. Preliminary report: Cyclosporin in treatment of severe active ulcerative colitis. Lancet. 1990;336:16–9.CrossRef
13.
go back to reference Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–9.CrossRef Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–9.CrossRef
14.
go back to reference D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–86.CrossRef D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–86.CrossRef
15.
go back to reference Raab Y, Sundberg C, Hällgren R, Knutson L, Gerdin B. Mucosal synthesis and release of prostaglandin E2 from activated eosinophils and macrophages in ulcerative colitis. Am J Gastroenterol. 1995;90:614–20.PubMed Raab Y, Sundberg C, Hällgren R, Knutson L, Gerdin B. Mucosal synthesis and release of prostaglandin E2 from activated eosinophils and macrophages in ulcerative colitis. Am J Gastroenterol. 1995;90:614–20.PubMed
16.
go back to reference Lasson A, Stotzer PO, Öhman L, Isaksson S, Sapnara M, Strid H. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9:26–32.PubMed Lasson A, Stotzer PO, Öhman L, Isaksson S, Sapnara M, Strid H. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9:26–32.PubMed
17.
go back to reference Hagiwara SI, Okayasu I, Fujiwara M, Matsuura M, Ohnishi H, Ito S, et al. Prostaglandin E-major urinary metabolite as a biomarker for pediatric ulcerative colitis activity. J Pediatr Gastroenterol Nutr. 2017;64:955–61.CrossRef Hagiwara SI, Okayasu I, Fujiwara M, Matsuura M, Ohnishi H, Ito S, et al. Prostaglandin E-major urinary metabolite as a biomarker for pediatric ulcerative colitis activity. J Pediatr Gastroenterol Nutr. 2017;64:955–61.CrossRef
18.
go back to reference Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35:642–7.CrossRef Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35:642–7.CrossRef
19.
go back to reference Vilkin A, Rozen P, Levi Z, Waked A, Maoz E, Birkenfeld S, et al. Performance characteristics and evaluation of an automated developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005;100:2519–25.CrossRef Vilkin A, Rozen P, Levi Z, Waked A, Maoz E, Birkenfeld S, et al. Performance characteristics and evaluation of an automated developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005;100:2519–25.CrossRef
20.
go back to reference Takashima S, Kato J, Hiraoka S, Nakarai A, Takei D, Inokuchi T, et al. Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test. Am J Gastroenterol. 2015;110:873–80.CrossRef Takashima S, Kato J, Hiraoka S, Nakarai A, Takei D, Inokuchi T, et al. Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test. Am J Gastroenterol. 2015;110:873–80.CrossRef
21.
go back to reference Fujiwara M, Okayasu I, Oritsu M, et al. Significant increase in prostaglandin E-main urinary metabolite by laxative administration: comparison with ulcerative colitis. Digestion. 2000;61(3):201–6.CrossRef Fujiwara M, Okayasu I, Oritsu M, et al. Significant increase in prostaglandin E-main urinary metabolite by laxative administration: comparison with ulcerative colitis. Digestion. 2000;61(3):201–6.CrossRef
22.
go back to reference Mak WY, Buisson A, Andersen MJ Jr, Lei D, Pekow J, Cohen RD, et al. Fecal calprotectin in assessing endoscopic and histological remission in patients with ulcerative colitis. Dig Dis Sci. 2018;63:1294–301.CrossRef Mak WY, Buisson A, Andersen MJ Jr, Lei D, Pekow J, Cohen RD, et al. Fecal calprotectin in assessing endoscopic and histological remission in patients with ulcerative colitis. Dig Dis Sci. 2018;63:1294–301.CrossRef
23.
go back to reference Narang V, Kaur R, Garg B, Mahajan R, Midha V, Sood N, et al. Association of endoscopic and histological remission with clinical course in patients of ulcerative colitis. Intest Res. 2018;6:55–61.CrossRef Narang V, Kaur R, Garg B, Mahajan R, Midha V, Sood N, et al. Association of endoscopic and histological remission with clinical course in patients of ulcerative colitis. Intest Res. 2018;6:55–61.CrossRef
24.
go back to reference Ponte A, Pinho R, Fernandes S, Rodrigues A, Alberto L, Silva JC, et al. Impact of histological and endoscopic remissions on clinical recurrence and recurrence-free time in ulcerative colitis. Inflamm Bowel Dis. 2017;23:2238–44.CrossRef Ponte A, Pinho R, Fernandes S, Rodrigues A, Alberto L, Silva JC, et al. Impact of histological and endoscopic remissions on clinical recurrence and recurrence-free time in ulcerative colitis. Inflamm Bowel Dis. 2017;23:2238–44.CrossRef
25.
go back to reference Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalization over 6 years of follow-up. Gut. 2016;65:408–14.CrossRef Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalization over 6 years of follow-up. Gut. 2016;65:408–14.CrossRef
Metadata
Title
Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis
Authors
Natsuki Ishida
Takahiro Miyazu
Ryosuke Takano
Satoshi Tamura
Shinya Tani
Takuma Kagami
Mihoko Yamade
Yasushi Hamaya
Moriya Iwaizumi
Satoshi Osawa
Takahisa Furuta
Hiroaki Miyajima
Ken Sugimoto
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2020
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-020-01256-5

Other articles of this Issue 1/2020

BMC Gastroenterology 1/2020 Go to the issue